Olaparib

Olaparib
Clinical data
Trade names	Lynparza, others
Other names	AZD-2281, MK-7339, KU0059436
AHFS/Drugs.com	Monograph
MedlinePlus	a614060
License data	US DailyMed: Olaparib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01XK01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 4-[(3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl) -4-fluorophenyl]methyl(2H)phthalazin-1-one;
CAS Number	763113-22-0 ;
PubChem CID	23725625;
IUPHAR/BPS	7519;
DrugBank	DB09074 ;
ChemSpider	23343272 ;
UNII	WOH1JD9AR8;
KEGG	D09730;
ChEBI	CHEBI:83766 ;
ChEMBL	ChEMBL521686 ;
PDB ligand	09L (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID60917988 ;
ECHA InfoCard	100.170.811
Chemical and physical data
Formula	C24H23FN4O3
Molar mass	434.471 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c4cccc2c4c(n[nH]c2=O)Cc(ccc1F)cc1C(=O)N3CCN(CC3)C(=O)C5CC5;
	InChI InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30) ; Key:FDLYAMZZIXQODN-UHFFFAOYSA-N ;
	(what is this?) (verify)

Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

In December 2014, olaparib was approved for use as a single agent by the European Medicines Agency (EMA) in the European Union and by the Food and Drug Administration (FDA) in the United States.